Literature DB >> 27654269

Combined Analysis of ChIP Sequencing and Gene Expression Dataset in Breast Cancer.

Pengfei Liu1, Wenhua Jiang2, Shiyong Zhou1, Jun Gao3, Huilai Zhang4.   

Abstract

Breast cancer is a common malignancy in women and contribute largely to the cancer related death. The purpose of this study is to confirm the roles of GATA3 and identify potential biomarkers of breast cancer. Chromatin Immunoprecipitation combined with high-throughput sequencing (ChIP-Seq) (GSM1642515) and gene expression profiles (GSE24249) were downloaded from the Gene Expression Omnibus (GEO) database. Bowtie2 and MACS2 were used for the mapping and peak calling of the ChIP-Seq data respectively. ChIPseeker, a R bioconductor package was adopted for the annotation of the enriched peaks. For the gene expression profiles, we used affy and limma package to do normalization and differential expression analysis. The genes with fold change >2 and adjusted P-Value <0.05 were screened out. Besides, BETA (Binding and Expression Target Analysis) was used to do the combined analysis of ChIP-Seq and gene expression profiles. The Database for Annotation, Visualization and Integrated Discovery (DAVID) was used for the functional enrichment analysis of overlapping genes between the target genes and differential expression genes (DEGs). What's more, the protein-protein interaction (PPI) network of the overlapping genes was obtained through the Human Protein Reference Database (HPRD). A total of 46,487 peaks were identified for GATA3 and out of which, 3256 ones were found to located at -3000 ~ 0 bp from the transcription start sites (TSS) of their nearby gene. A total of 236 down- and 343 up-regulated genes were screened out in GATA3 overexpression breast cancer samples compared with those in control. The combined analysis of ChIP-Seq and gene expression dataset showed GATA3 act as a repressor in breast cancer. Besides, 68 overlaps were obtained between the DEGs and genes included in peaks located at -3000 ~ 0 bp from TSS. Gene Ontology (GO) terms and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways related to cancer progression and gene regulation were found to be enriched in those overlaps. In the PPI network, NDRG1, JUP and etc. were found to directly interact with large number of genes, which might indicate their important roles in the progression of breast cancer.

Entities:  

Keywords:  Breast cancer; Chromatin Immunoprecipitation combined with high-throughput sequencing (ChIP-seq); Human protein reference database (HPRD); Protein-protein interaction (PPI)

Mesh:

Year:  2016        PMID: 27654269     DOI: 10.1007/s12253-016-0116-z

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN: 1219-4956            Impact factor:   3.201


  30 in total

1.  BRCA1 and GATA3 corepress FOXC1 to inhibit the pathogenesis of basal-like breast cancers.

Authors:  D Tkocz; N T Crawford; N E Buckley; F B Berry; R D Kennedy; J J Gorski; D P Harkin; P B Mullan
Journal:  Oncogene       Date:  2011-11-28       Impact factor: 9.867

2.  MicroRNA-183 Functions As an Oncogene by Regulating PDCD4 in Gastric Cancer.

Authors:  Chenglong Li; Li Deng; Qiaoming Zhi; Qingyou Meng; Aimin Qian; Hongfei Sang; Xiaoqiang Li; Jiazeng Xia
Journal:  Anticancer Agents Med Chem       Date:  2016       Impact factor: 2.505

3.  Gene Expression Profiling of Evening Fatigue in Women Undergoing Chemotherapy for Breast Cancer.

Authors:  Kord M Kober; Laura Dunn; Judy Mastick; Bruce Cooper; Dale Langford; Michelle Melisko; Alan Venook; Lee-May Chen; Fay Wright; Marilyn Hammer; Brian L Schmidt; Jon Levine; Christine Miaskowski; Bradley E Aouizerat
Journal:  Biol Res Nurs       Date:  2016-03-08       Impact factor: 2.522

4.  Tryptophan-induced pathogenesis of breast cancer.

Authors:  Zhu-Gen Cao; Xiao-Bing Qin; Fang-Fang Liu; Lei-Lei Zhou
Journal:  Afr Health Sci       Date:  2015-09       Impact factor: 0.927

Review 5.  The role of GATA3 in breast carcinomas: a review.

Authors:  Rebecca Asch-Kendrick; Ashley Cimino-Mathews
Journal:  Hum Pathol       Date:  2015-10-28       Impact factor: 3.466

Review 6.  [Immunotherapy opportunities in breast cancer].

Authors:  Lajos Pusztai; Andrea Ladányi; Borbála Székely; Magdolna Dank
Journal:  Magy Onkol       Date:  2015-12-19

Review 7.  GATA3 in Breast Cancer: Tumor Suppressor or Oncogene?

Authors:  Motoki Takaku; Sara A Grimm; Paul A Wade
Journal:  Gene Expr       Date:  2015

8.  GATA3 inhibits lysyl oxidase-mediated metastases of human basal triple-negative breast cancer cells.

Authors:  I M Chu; A M Michalowski; M Hoenerhoff; K M Szauter; D Luger; M Sato; K Flanders; A Oshima; K Csiszar; J E Green
Journal:  Oncogene       Date:  2011-09-05       Impact factor: 9.867

9.  The proto-oncogene c-Src and its downstream signaling pathways are inhibited by the metastasis suppressor, NDRG1.

Authors:  Wensheng Liu; Fei Yue; Minhua Zheng; Angelica Merlot; Dong-Hun Bae; Michael Huang; Darius Lane; Patric Jansson; Goldie Yuan Lam Lui; Vera Richardson; Sumit Sahni; Danuta Kalinowski; Zaklina Kovacevic; Des R Richardson
Journal:  Oncotarget       Date:  2015-04-20

10.  E2F7 regulates transcription and maturation of multiple microRNAs to restrain cell proliferation.

Authors:  Jone Mitxelena; Aintzane Apraiz; Jon Vallejo-Rodríguez; Marcos Malumbres; Ana M Zubiaga
Journal:  Nucleic Acids Res       Date:  2016-03-09       Impact factor: 16.971

View more
  4 in total

1.  Superenhancer-transcription factor regulatory network in malignant tumors.

Authors:  Yuan Liang; Linlin Li; Tian Xin; Binru Li; Dalin Zhang
Journal:  Open Med (Wars)       Date:  2021-10-18

2.  Ral GEF with the PH Domain and SH3 Binding Motif 1 Regulated by Splicing Factor Junction Plakoglobin and Pyrimidine Metabolism Are Prognostic in Uterine Carcinosarcoma.

Authors:  Hongjun Guo; Siqiao Wang; Aiqing Xie; Wenhuizi Sun; Chenlu Wei; Shuyuan Xian; Huabin Yin; Mingxiao Li; Hanlin Sun; Hong Li; Tong Meng; Jie Zhang; Zongqiang Huang
Journal:  Dis Markers       Date:  2021-10-28       Impact factor: 3.434

3.  HOXC6 impacts epithelial-mesenchymal transition and the immune microenvironment through gene transcription in gliomas.

Authors:  Hui Huang; Zhengyuan Huo; Jiantong Jiao; Wei Ji; Jin Huang; Zheng Bian; Bin Xu; Junfei Shao; Jun Sun
Journal:  Cancer Cell Int       Date:  2022-04-29       Impact factor: 6.429

4.  T5224, RSPO2 and AZD5363 are novel drugs against functional pituitary adenoma.

Authors:  Sheng Zhong; Bo Wu; Jiahui Li; Xinhui Wang; Shanshan Jiang; Fangfei Hu; Gaojing Dou; Yuan Zhang; Chunjia Sheng; Gang Zhao; Yunqian Li; Yong Chen
Journal:  Aging (Albany NY)       Date:  2019-10-26       Impact factor: 5.682

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.